Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients

Julia R. Coleman1 | Hiroshi Deguchi2 | Taichi K. Deguchi2 | Mitchel J. Cohen1,3 | Ernest E. Moore1,3 | John H. Griffin2,4

BRIEF REPORT

Abstract

Background: Skeletal muscle myosin (SkM) molecules are procoagulant both in vitro and in vivo. The association of plasma SkM isoforms with blood coagulability and hemostatic capacity has not been defined.

Objectives: We hypothesized that coagulopathy in acutely injured patients is associated with procoagulant plasma SkM heavy chain levels.

Methods: To test this hypothesis, citrated whole blood and plasma from 104 trauma patients were collected and studied to obtain data for rapid thrombelastography, international normalized ratios, and plasma SkM levels. Coagulability parameters were dichotomized by the threshold for the hypercoagulable trauma-induced coagulopathy.

Results: Lower plasma full-length SkM heavy chain (full-SkM) levels were associated with higher international normalized ratio values (p = .03). The full-SkM levels were also associated with a lower rate of clot propagation (thrombelastography angle <65°) (p = .004), and plasma full-SkM levels were positively correlated with the thrombelastography angle (r² = .32, p = .0007). The trauma patient group with the lower plasma full-SkM levels showed an association with lower clot strength (maximum amplitude <55 mm) (p = .002), and plasma full-SkM levels positively correlated with maximum amplitude (r² = .27, p = .005). Hyperfibrinolysis was associated with significantly decreased full-SkM levels (p = .03). Trauma patients who required red blood cells and fresh frozen plasma transfusions had lower plasma full-SkM levels compared with those without transfusions (p = .04 and .02, respectively).

Conclusions: In acutely injured trauma patients, lower levels of plasma full-SkM levels are linked to hypocoagulability in trauma-induced coagulopathy, implying that SkM plays a role in the hemostatic capacity in trauma patients and may contribute to trauma-induced coagulopathy.

KEYWORDS

blood coagulation, blood transfusion, myosin, thrombin, trauma
1 | INTRODUCTION

Thrombin generation is central to the hemostatic balance, and insufficient thrombin generation is linked to bleeding risk.\(^1\) We have previously identified significant association of full-length skeletal muscle myosin (SkM) molecules with hemostatic capacity, specifically with increasing thrombin generation both in vitro and in vivo.\(^2\)\(^-\)\(^9\)

SkM is a molecular motor and conventional muscle myosin and is a dimer of heterotrimers, with each trimer containing one heavy chain (HC), one essential light chain, and one regulatory light chain.\(^6\)\(^,\)\(^10\) When the tail of the full length of SkM HC (240 kDa) (defined as full-SkM) is cleaved, smaller fragments, HMM HC (160 kDa) or S1 HC (95 kDa), are generated. These three SkM HC isoform antigen phenotypes have been identified in human plasma, one of which is associated with isolated pulmonary embolism, suggesting the potential pathological contribution of procoagulant large SkM isoforms to thrombotic disease.\(^11\) However, the association of endogenous plasma SkM isoforms with hemostatic capacity has not been explored and defined.

Mechanical trauma disrupts skeletal muscle, and these damaged tissues expose or release SkM to the blood\(^12\)\(^-\)\(^20\); this could provide previously unavailable sites for regulation of thrombin generation. Exposed or released SkM's procoagulant actions may contribute to either hemostasis or thrombosis\(^21\); however, the effect of SkM on coagulation has not been comprehensively examined in trauma patients. Moreover, the mechanisms of trauma-induced coagulopathy have yet to be fully elucidated. A pilot exploratory study suggested that the circulating SkM in human plasma contributes significantly more to the procoagulant potential of trauma patient’s plasma than to that of healthy control’s plasma.\(^2\) Therefore, for this study, because SkM appears to have physiological procoagulant functions, we hypothesized that there are associations of plasma SkM isoform levels with blood coagulability in trauma patients.

2 | METHODS

2.1 | Plasma samples from trauma patients

Citrated whole blood and plasmas from 24 healthy controls and 104 adult trauma patients (median age 34 years, 71% male, 66% blunt trauma mechanisms, median new injury severity score (NISS) of 33) were collected at an urban level 1 trauma center (Ernest E Moore Shock Trauma Center at Denver Health Medical Center in Colorado) (Table 1). Because sex and age did not influence SkM isoform levels based on our unpublished data for the healthy control cohort in the Scripps Venous Thrombosis Registry,\(^8\) we did not analyze to coordinate age- and sex-matched controls. All blood samples were drawn from patients immediately on arrival to the emergency department before any interventions, and plasma was prepared within 2 h. The study was approved by the respective regional institutional review boards and performed under the waiver of consent.

Essentials

- Skeletal muscle myosin (SkM) added to blood exerts procoagulant activity in vitro.
- Thrombelastography studies tested relationships of endogenous SkM to trauma blood coagulopathy.
- A SkM heavy chain isoform in trauma patients plasma was correlated with coagulability parameters.
- SkM may contribute to hemostasis in trauma patients and/or to trauma-induced hypocoagulability.

2.2 | Procedures

Citrated rapid thromboelastography (TEG) assay data induced by tissue factor and kaolin using fresh whole blood\(^22\)\(^-\)\(^25\) and international normalized ratio (INR) data were obtained at the clinical laboratory, in addition to collection of basic demographic, injury-related, and clinical outcome data. Thromboelastography yields the following measurements: activating clotting time (time to clot formation), angle (rate of clot propagation, an effect of fibrinogen), maximum amplitude (MA, clot strength), and LY30 (30 min after MA). Fibrinolytic phenotypes are defined by LY30 and include hyperfibrinolysis, physiologic lysis, and shutdown. Plasma SkM HC isoforms (full-length SkM HC (240 kDa band, defined as full-SkM), HMM HC (160-kDa band), and S1 HC (95-kDa band)) were detected by immunoblotting\(^22\) and were quantified by Li-Cor Odyssey and Li-Cor Image Studio Lite v4.0 software. The relative fluorescence unit values for SkM bands were determined using the standard curve of the dilution of pooled normal plasma subjects (George King Bio-Medical, Inc. Overland Park, KS). Calibration of blots using pooled plasma showed a linear dynamic range of 0.25 to 2 μL (12.5% to 200% of control plasma). The intra- and interassay coefficient of variations for measuring each band was determined by analyzing the immunoblotting of 22 identical plasma samples on the same gel and on seven different gels for three different levels of each SkM isoform, respectively. The intra-assay coefficients of variability (CV%) for SkM isoform quantification were <10% for all isoforms (9.98%, 8.54%, and 9.68% for full-SkM, SkM-HMM HC, and SkM-S1 HC, respectively), and the interassay CV% values for SkM isoform quantification of three levels of diluted pooled plasma (50%, 100%, and 200%) were <10% for all isoforms (8.53%, 6.97%, and 9.40%, for full-SkM, SkM-HMM HC, and SkM-S1 HC, respectively). These intra- and inter-CV% assay values show that this immunoblotting method reliably quantified the relative amounts of each SkM isoform band.

Control experiments showed that variations in the time between blood collection and plasma preparation of up to 3 h did not influence plasma full-SkM levels because full-SkM levels were not significantly different (<10%) when blood was collected for analysis from four healthy adult controls, and the plasma preparation times were 30, 60, 120, and 180 min after blood collection.
TABLE 1 Description of study population by demographics, injury, physiology, coagulation, and clinical outcomes

| Demographics | Age, y | 33.6 (25.5–50.3) |
|--------------|-------|------------------|
| Male, n (%)  | 74 (71%) |

| Injury characteristics | Blunt mechanism, n (%) | 69 (66%) |
|------------------------|------------------------|----------|
| NISS                   | 33 (22–43)             |
| GCS                    | 14 (3–15)              |
| TBI, n (%)             | 45 (43%)               |

| Physiologic markers     | SBP (mm Hg) | 102 (82–132) |
|-------------------------|-------------|--------------|
|                         | BD (mEq/L)  | 7.9 (5.0–12.0) |
|                         | Lactate (mmol/L) | 4.3 (3.1–8.1) |

| Conventional coagulation assays | PT/INR | 1.1 (1.0–1.5) |
|---------------------------------|--------|--------------|
|                                 | PTT, s | 29.5 (25.8–40.9) |

| Initial (field or hospital arrival) TEG measurements | ACT, s | 121 (113–144) |
|------------------------------------------------------|--------|--------------|
|                                                      | Angle, degrees | 69.5 (62.5–74.7) |
|                                                      | MA, mm | 60.5 (51.5–66.0) |
|                                                      | LY30 (%) | 1.9 (0.6–8.9) |

| Outcomes                              | Mortality, n (%) | 25 (24%) |
|---------------------------------------|------------------|---------|
| Transfusion (≥1 U RBC) in first 24 h, n (%) | 63 (61%) |
| Units of RBC/first 6 h (among patients who received ≥1 U RBC/6 h) | 6 (3–10) |
| Massive transfusion, n (%)             | 22 (21%) |

Note: Continuous variables expressed as median (interquartile range) and proportions expressed as percentages (N). Citrated plasmas from 104 trauma patients collected at an urban level 1 trauma center. Abbreviations: ACT, activated clotting time; BD, base deficit; GCS, Glasgow Coma Score; LY30, fibrinolysis 30 min after MA; MA, maximum amplitude; NISS, new injury severity score; PT/INR, prothrombin time/international normalized ratio; PTT, partial thromboplastin time; RBC, red blood cell transfusion; SBP, systolic blood pressure; TBI, traumatic brain injury.

3 | RESULT AND DISCUSSION

Overall, whole blood was collected from 104 trauma patients (Table 1), and deidentified plasma samples were analyzed for levels of the plasma SkM heavy chain isoforms by quantitative immunoblotting. The values for various plasma SkM isoform concentrations (full-SkM, SkM-HMM, and SkM-S1) in the trauma group were not statistically different from those of the control group.

Thromboelastography measurements were dichotomized by the optimal transfusion threshold levels that are used to guide hemostatic resuscitation for patients at risk for massive transfusion and considered as hypocooagulable trauma-induced coagulopathy. Among the measured SkM levels, only full-SkM levels showed significant associations with hypocooagulable trauma-induced coagulopathy based on the following analysis. There were significant differences in full-SkM levels based on multiple TEG measurements. Specifically, patients with an angle of <65° (n = 27) had a median full-SkM level of 33.2% versus 117.5% in patients with normal angle ≥65° (n = 77) (p = .004) (Table 2). Notably, the angle reflects the speed of fibrin accumulation and polymerization corresponding to the thrombin burst phase. Increased level of thrombin activity in whole blood by procoagulant activities of SkM (ie, prothrombinase cofactor and antihemarin/antithrombin activities) may be reflected by the TEG angle measurement. Further, patients with a depressed MA <55 mm (n = 36) had a significantly lower median SkM level of 34.0% versus 123.9% in patients with MA ≥55 mm (n = 68) (p = .002) (Table 2). The MA represents clot strength as determined by platelet number and function as well as fibrin cross-linking by factor XIIa to form a stable clot. Because thrombin activates factor XIII and platelets, as well as factor XI, MA could reflect thrombin activities affected by full-SkM plasma level. Further, when TEG measurements were used as continuous values, plasma full-SkM levels positively correlated with the TEG angle (r² = .32, p = .0007) and with MA (r² = .27, p = .005).

In addition to the associations of full-SkM with clot propagation and strength, hyperfibrinolysis (defined by TEG fibrinolysis 30 min after MA [LY30] of ≥3.0% and present in 34 patients) was associated with significantly decreased full-SkM levels (median 38.2% vs 104.3% in the 70 patients with physiologic fibrinolysis [LY30 0.9%–2.9%] or fibrinolytic shutdown [LY30 < 0.9%], p = .03) (Table 2). This association of the full-SkM deficiency with hyperfibrinolysis may be supported by the fact that SkM was antifibrinolytic in one study because of robust SkM-dependent thrombin generation via activation of thrombin activatable fibrinolysis inhibitor. This relationship between hyperfibrinolysis and SkM levels is relevant as hyperfibrinolysis has been linked to high levels of mortality in trauma patients. Thus, full-SkM deficiency was here associated with not only hypoagulability but also with hyperfibrinolysis, each of which may induce more bleeding. Further supporting this point, patients who presented with a pathologically elevated INR of >1.3, considered a hypoaguable condition, had significantly lower levels of full-SkM (median 76.0% vs 119%, p = .02) (Table 2), supporting the association of full-SkM levels with coagulability in TEG, and implying full-SkM contributes to the coagulation system. These data could be further substantiated in future studies using complementary approaches to measure directly thrombin generation (eg, calibrated automated thrombinoigraphy) or coagulation markers (eg, prothrombin fragment 1-2), which could further define the role of full-SkM affecting thrombin activity.

When the association of plasma full-SkM levels with clinical markers of coagulopathy was examined, trauma patients who required red blood cell and fresh frozen plasma transfusions had lower plasma full-SkM levels compared with the group without blood transfusion (p = .04 and .02, respectively) (Table 2). These data are consistent with the hypothesis that full-SkM may play a role in the hemostatic capacity in trauma patients, and, when this mechanism is deranged, may contribute to trauma-induced coagulopathy.
full-SkM-deficient patients had a poorer hemostatic function, leading to more bleeding and required blood transfusion.

Muscle damage (e.g., acute trauma, rhabdomyolysis) increases the total SkM HC antigen levels; however, presently, the metabolic mechanisms regulating plasma SkM levels are not known. In our trauma group, the plasma SkM levels did not differ by injury severity (median 90.9% in patients with NISS \(< 25 \ [n = 9]\) vs 104.4% in patients with NISS >15 \([n = 95]\), nor as compared with healthy volunteers. However, there were significantly higher levels of SkM found circulating in trauma patients’ blood after high-energy penetrating injuries (median 141.3% in penetrating mechanism \([n = 36]\) vs 114.6% in blunt mechanism \([n = 68]\), \(p = .04\)). No differences were seen by shock, as defined as systolic blood pressure <90 upon presentation (median 76.6% in shocked patients \([n = 30]\) vs 116.6% in nonshocked patients \([n = 69]\), \(p = .06\)). Thus, the injury mechanism was associated with differences in SkM levels; however, more studies are required to characterize the regulatory mechanisms for SkM levels in trauma patients.

The discovery here that the deficiency of full-SkM is associated with hypocoagulable trauma-induced coagulopathy and bleeding relied on newly developed immunoblotting methodology with acceptable intra- and inter-CV% values for plasma SkM. Such immunoblotting methods are not conveniently available in many laboratories, so the development of easier techniques to quantify SkM isoforms (e.g., specific ELISA assays) could extend analyses of SkM isoforms for clinical research.

In conclusion, our findings suggest that, in some trauma patients, full-SkM deficiency is associated with hypocoagulable trauma-induced coagulopathy and hyperfibrinolysis, which leads to more bleeding. Thus, the full-SkM isoform may act as a procoagulant and prohemostatic agent in trauma patients. Therefore, in the setting of acute injury, extensive tissue damage with SkM exposure or release into the bloodstream might enhance plasma full-SkM-induced thrombin generation, thereby contributing to hemostasis. Therefore, the lack of full-SkM, for some reasons (e.g., injury type or consumption at the bleeding site), may cause deficiency of hemostasis. In this scenario, supplemented full-SkM may enhance hemostatic capacity.

**ACKNOWLEDGMENTS**

This work was supported by the National Institutes of Health grants (R01HL133728 and R01HL142975 [J.H.G.], T32 GM008315 and P50 GM049222 [E.E.M.]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other sponsors of the project.
CONFLICTS OF INTEREST
The authors declare no competing financial interests.

AUTHOR CONTRIBUTIONS
Hiroshi Deguchi and John H. Griffin participated in the conception of the study and the overall supervision and integration of all studies. Taichi K. Deguchi and Hiroshi Deguchi were responsible for performing the quantification of plasma SkM. Julia R. Coleman and Ernest E. Moore performed TEG assays. Julia R. Coleman, Mitchell J. Cohen, and Ernest E. Moore were responsible for organizing clinical data and statistical analysis. Hiroshi Deguchi, John H. Griffin, Julia R. Coleman, and Ernest E. Moore analyzed and interpreted the data. Hiroshi Deguchi and John H. Griffin were responsible for writing the manuscript draft, and all authors reviewed and approved the final manuscript.

INFORMED CONSENT
This study was approved by the Colorado Multiple Institutional Review Board (COMIRB 18-0625), and all subjects provided informed consent.

ORCID
Julia R. Coleman https://orcid.org/0000-0001-5610-9249
Hiroshi Deguchi https://orcid.org/0000-0002-7721-1207
John H. Griffin https://orcid.org/0000-0002-4302-2547

REFERENCES
1. Coleman JR, Moore EE, Samuels JM, et al. Whole blood thrombin generation in severely injured patients requiring massive transfusion. J Am Coll Surg. 2021;232:709-716.
2. Deguchi H, Sinha RK, Marchese P, et al. Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood. 2016;128:1870-1878.
3. Deguchi H, Guo Z, Hayat M, et al. Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation. J Biol Chem. 2019;294:15176-15181.
4. Morla S, Deguchi H, Griffin JH. Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity. J Thromb Haemost. 2021;19:7-19.
5. Morla S, Deguchi H, Fernández JA, Ruf W, Brekken RA, Griffin JH. Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. Blood. 2021;137:1839-1842.
6. Deguchi H, Morla S, Griffin JH. Novel blood coagulation molecules: skeletal muscle myosin and cardiac myosin. J Thromb Haemost. 2021;19:7-19.
7. Zilberman-Rudenko J, Deguchi H, Shukla M, et al. Cardiac myosin promotes thrombin generation and coagulation in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2020;40:901-913.
8. Deguchi H, Shukla M, Hayat M, Torkamani A, Elias DJ, Griffin JH. Novel exomic rare variants associated with venous thrombosis. Br J Haematol. 2020;190:783-786.
9. Coleman JR, Moore EE, Zilberman-Rudenko J, et al. Cardiac and skeletal muscle myosin exert procoagulant effects. Shock. 2019;52:554-555.
10. Sellers JR. Myosins: a diverse superfamily. Biochim Biophys Acta. 2000;1496:3-22.
11. Deguchi TK, Deguchi H, Guo Z, Elias DJ, Griffin JH. Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. Thromb Res. 2020;189:88-92.
12. Guerrero M, Guiu-Comadevall M, Cadefau JA, et al. Fast and slow myosins as markers of muscle injury. Br J Sports Med. 2008;42:581-584.
13. Liu T, Qian WJ, Gritsenko MA, et al. High dynamic range characterization of the trauma patient plasma proteome. Mol Cell Proteomics. 2006;5:1899-1913.
14. Erlacher P, Lercher A, Falkensammer J, et al. Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. Clin Chim Acta. 2001;306:27-33.
15. Lofberg M, Tahtela R, Harkonen M, Somer H. Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis. Diagnostic specificity of new biochemical markers. Arch Neurol. 1995;52:1210-1214.
16. Onuoha GN, Alpar EK, Laprade M, Rada D, Pau B. Levels of myosin heavy chain fragment in patients with tissue damage. Arch Med Res. 2001;32:27-29.
17. Onuoha GN, Alpar EK, Laprade M, Rada D, Pau B. Effects of bone fracture and surgery on plasma myosin heavy chain fragments of skeletal muscle. Clin Invest Med. 1999;22:180-184.
18. Mair J, Koller A, Artner-Dworzak E, et al. Effects of exercise on plasma myosin heavy chain fragments and MRI of skeletal muscle. J Appl Physiol. 1985;1992(72):656-663.
19. Sorichter S, Mair J, Koller A, et al. Creatine kinase, myosin heavy chains and magnetic resonance imaging after eccentric exercise. J Sports Sci. 2001;19:687-691.
20. Mair J, Mayr M, Müller E, et al. Rapid adaptation to eccentric exercise-induced muscle damage. Int J Sports Med. 1995;16:352-356.
21. Monroe DM. Adding some muscle to blood coagulation. Blood. 2016;128:1786-1787.
22. Schmidt AE, Israel AK, Refaai MA. The utility of thromboelastography to guide blood product transfusion. Am J Clin Pathol. 2019;152:407-402.
23. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy, Nat Rev Dis Primers. 2021;7:30. doi:10.1038/s41572-021-00264-3
24. Coleman JR, Moore EE, Samuels JM, et al. Trauma resuscitation consideration: sex matters. J Am Coll Surg. 2019:228:760-768.e1.
25. Einersen PM, Moore EE, Chapman MP, et al. Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion. J Trauma Acute Care Surg. 2017;82:114-119.
26. Gonzalez E, Moore EE, Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care Clin. 2017;33:119-134. doi:10.1016/j.ccc.2016.09.002
27. Chapman MP, Moore EE, Moore HB, et al. The, “death diamond”: rapid thrombelastography identifies lethal hyperfibrinolysis. J Trauma Acute Care Surg. 2015;79:925-929.
28. Leeper CM, Kutch er M, Nasr I, et al. Acute traumatic coagulopathy in critically injured pediatric population: definition, trend over time, and outcomes. J Trauma Acute Care Surg. 2016;81:34-41.
29. Cohen MJ, Kutch er B, Redick B, et al. Clinical and mechanistic drivers of acute traumatic coagulopathy. J Trauma Acute Care Surg. 2013;75:540-547.
30. Leclerc-Gagne K. Survival analysis after head injury: is a normal INR reassuring? Crit Care. 2013;17:P336.

How to cite this article: Coleman JR, Deguchi H, Deguchi TK, Cohen MJ, Moore EE, Griffin JH. Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients. J Thromb Haemost. 2022;20:1385-1389. doi:10.1111/jth.15695